BOSTON – Janssen Pharmaceuticals Inc. is seeking to achieve a broad improvement in the treatment of hepatitis B, pursuing a “functional cure” via a variety of mechanisms and modalities that it hopes will come together in a combination therapy regimen similar to those that changed the landscape in HIV and hepatitis C.
The Johnson & Johnson subsidiary presented a set of posters and abstracts during the American Association for the Study of Liver Diseases conference Nov. 11-15 that detailed its work to address the hepatitis B virus (HBV), including capsid assembly modulation, small interfering RNA (siRNA) therapeutics, Toll-like receptor-7 (TLR7) agonism, a DNA-based vaccine and a delivery technology for one or more of these potential therapies with a lipid delivery system called LUNAR
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?